Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8771797 | 0.97 | MAPT (0.54) | MAPTALDH1A1LMNAHDAC3HDAC11 | |
| SCHEMBL16775458 | 0.97 | MAPT (0.54) | MAPTALDH1A1LMNAHDAC3HDAC11 | |
| SCHEMBL8771609 | 0.97 | MAPT (0.54) | MAPTALDH1A1LMNAHDAC3HDAC11 | |
| SCHEMBL20805873 | 0.93 | MAPT (0.55) | MAPTALDH1A1LMNAHDAC3HDAC11 | |
| SCHEMBL1964450 | 0.91 | ALDH1A1 (0.57) | MAPTALDH1A1LMNAHDAC3HDAC11 | |
| SCHEMBL1964453 | 0.91 | ALDH1A1 (0.57) | MAPTALDH1A1LMNAHDAC3HDAC11 | |
| SCHEMBL12125158 | 0.89 | ALDH1A1 (0.53) | MAPTALDH1A1LMNAHDAC3HDAC11 | |
| SCHEMBL12125152 | 0.88 | ALDH1A1 (0.54) | MAPTALDH1A1LMNAHDAC3HDAC11 | |
| SCHEMBL14207675 | 0.88 | LMNA (0.54) | MAPTALDH1A1LMNAHDAC3HDAC11 | |
| SCHEMBL6113736 | 0.87 | ALDH1A1 (0.56) | MAPTALDH1A1LMNAHDAC3HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970326-B1 | SUBSTITUTED 5,6-RING-FUSED NAPHTHOPYRAN COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9309455-B2 | Indeno-fused ring compounds | TRANSITIONS OPTICAL, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309455-B2 | Indeno-fused ring compounds | TRANSITIONS OPTICAL, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140166948-A1 | INDENO-FUSED RING COMPOUNDS | TRANSITIONS OPTICAL LIMITED (IE) | 2014-06-19 | — | — | US | disclosed |
| US-20140166948-A1 | INDENO-FUSED RING COMPOUNDS | TRANSITIONS OPTICAL LIMITED (IE) | 2014-06-19 | — | — | US | disclosed |
| US-20120126185-A1 | INDENO-FUSED RING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120126185-A1 | INDENO-FUSED RING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120126185-A1 | INDENO-FUSED RING COMPOUNDS | CRY2, SQOR, INTS6 | MAPT 2624/4885ALDH1A1 498/4885LMNA 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.